- Free from Publisher I Bogacka, H Xie, GA Bray, SR Smith - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Pioglitazone treatment increased the expression of genes involved in
glycerol-3-phosphate synthesis. The mRNA expression of PEPCK-C and
glycerol-3-phosphate dehydrogenase (GPDH) increased (P < 0.01) in patients ... Cited by 103 - Related articles - BL Direct - All 8 versions
GD Tan, BA Fielding, JM Currie, SM … - Diabetologia, 2005 - Springer Abstract Aims/hypothesis: We investigated the effects of rosiglitazone on NEFA
and triglyceride metabolism in type 2 diabetes. Methods: In a double-blind,
placebo-con- trolled, cross-over study of rosiglitazone in diet-treated ... Cited by 85 - Related articles - All 2 versions
E Duplus, C Benelli, AF Reis, F Fouque, G … - Biochimie, 2003 - Elsevier Cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C) is the key enzyme in
glyceroneogenesis, an important metabolic pathway in adipocytes for
reesterification of fatty acids during fasting. Dysregulation of ... Cited by 21 - Related articles - All 4 versions
GD Tan, C Debard, C Tiraby, SM Humphreys, … - Nature az index, 2003 - nature.com Jump to main content; Jump to navigation; nature.com homepage; Publications AZ index;
Browse by subject. My account; Submit Manuscript; Register; Subscribe. Login ... Cited by 29 - Related articles - All 3 versions
- ►diabetesjournals.org M Laplante, H Sell, KL MacNaul, D Richard, … - Diabetes, 2003 - Am Diabetes Assoc This study sought to determine whether the adipose depot−specific
(subcutaneous [SF] vs. visceral [VF]) action of peroxisome
proliferator−activated receptor-γ (PPAR-γ) agonists on fat deposition ... Cited by 77 - Related articles - BL Direct - All 5 versions
SR Smith, L de Jonge, J Volaufova, Y Li, H … - Metabolism, 2005 - Elsevier We performed a randomized, double-blind, placebo-controlled trial in 48 men and
women with type 2 diabetes who had not previously received treatment with TZDs.
Patients were treated for 24 weeks with 45 mg/d of pioglitazone or a ... Cited by 70 - Related articles - All 9 versions
M Glorian, E Duplus, EG Beale, DK Scott, DK … - Biochimie, 2001 - Elsevier Phosphoenolpyruvate carboxykinase (PEPCK) is the key enzyme in
glyceroneogenesis, an important metabolic pathway that functions to restrain the
release of non-esterified fatty acids (NEFAs) from adipocytes. The ... Cited by 43 - Related articles - All 4 versions
M Bajaj, S Suraamornkul, LJ Hardies, T … - International journal of obesity, 2004 - nature.com METHODS: HFC (magnetic resonance spectroscopy) and basal plasma resistin
concentration were quantitated before and after PIO treatment (45 mg/day) for 16
weeks. Subjects received a 3 h euglycemic insulin (100 mU/m 2 /min) clamp ... Cited by 108 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org G Boden, C Homko, M Mozzoli, LC Showe, C … - Diabetes, 2005 - Am Diabetes Assoc Thiazolidinediones (TZDs) are a new class of insulin-sensitizing drugs. To
explore how and in which tissues they improve insulin action, we obtained fat
and muscle biopsies from eight patients with type 2 diabetes before and 2 ... Cited by 53 - Related articles - All 5 versions
- ►nih.gov JR Jones, C Barrick, KA Kim, J Lindner, B … - Proceedings of the National Academy of Sciences, 2005 - National Acad Sciences Peroxisome proliferator-activated receptor γ (PPARγ) plays a crucial role in
adipocyte differentiation, glucose metabolism, and other physiological
processes. To further explore the role of PPARγ in adipose tissues, we ... Cited by 77 - Related articles - All 10 versions
